{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:58:42Z","timestamp":1783511922878,"version":"3.55.0"},"reference-count":36,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Teriparatide [rhPTH (1-34)] is an established anabolic agent for the treatment of severe osteoporosis. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, have demonstrated antiresorptive properties, but their impact on the anabolic efficacy of rhPTH remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate whether concurrent statin therapy influences changes in bone mineral density (BMD) and bone turnover markers in women receiving rhPTH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 104 postmenopausal women with severe osteoporosis who completed 24 months of daily rhPTH (20\u2005mcg subcutaneously) and biweekly cholecalciferol (25 000\u2005IU). Patients were stratified by statin use. BMD at the lumbar spine and femoral neck was assessed at baseline and study completion. Bone turnover markers\u2014alkaline phosphatase, osteocalcin, and C-terminal telopeptide of type I collagen\u2014were measured every 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty patients were statin users and 74 were nonusers. Statin users experienced lumbar spine BMD gain from 0.71 \u00b1 0.16 to 0.79 \u00b1 0.14\u2005g\/cm\u00b2 (P = .01) and a trend toward femoral neck improvement from 0.53 \u00b1 0.24 to 0.62 \u00b1 0.12\u2005g\/cm\u00b2 (P = .07). Nonusers also showed a lumbar spine BMD rise from 0.70 \u00b1 0.10 to 0.77 \u00b1 0.11\u2005g\/cm\u00b2 (P = .001), with no significant femoral neck BMD change from 0.60 \u00b1 0.11 to 0.58 \u00b1 0.15\u2005g\/cm\u00b2 (P = .5). At the end of the observation period, C-terminal telopeptide of type I collagen levels were significantly lower in statin users compared to nonusers (0.37 \u00b1 0.29 vs 0.66 \u00b1 0.47\u2005ng\/mL, P = .007). Conversely, no significant intergroup differences were observed for alkaline phosphatase and osteocalcin throughout the observation period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Statin use does not impair the anabolic efficacy of rhPTH in increasing BMD in postmenopausal women with severe osteoporosis, but it provides additional antiresorptive benefits during rhPTH therapy. These findings support the continued use of statins and highlight the need for further prospective studies exploring synergistic effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf523","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T12:03:45Z","timestamp":1758110625000},"page":"e691-e696","source":"Crossref","is-referenced-by-count":2,"title":["Statins Do Not Affect Bone Anabolism in Older Women Treated With Teriparatide"],"prefix":"10.1210","volume":"111","author":[{"given":"Cecilia","family":"Oliveri","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University Hospital of Messina , 98125 Messina ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Xourafa","sequence":"additional","affiliation":[{"name":"Unit of Thalassemia, Policlinico \u201cG. Rodolico\u201d , 95123 Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunziata","family":"Morabito","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University Hospital of Messina , 98125 Messina ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Gaudio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University Hospital of Catania , 95123 Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Politi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University Hospital of Messina , 98125 Messina ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Rigshospitalet , 2100 Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-0439","authenticated-orcid":false,"given":"Salvatore","family":"Minisola","sequence":"additional","affiliation":[{"name":"Department of Clinical, Internal, Anesthesiologic, and Cardiovascular Sciences, \u201cSapienza\u201d University of Rome , 00161 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3890-2299","authenticated-orcid":false,"given":"Antonino","family":"Catalano","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University Hospital of Messina , 98125 Messina ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"issue":"10169","key":"2026021918525313400_dgaf523-B1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"2026021918525313400_dgaf523-B2","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1016\/S2666-7568(21)00172-0","article-title":"Global, regional, and national burden of bone fractures in 204 countries and territories, 1990-2019: a systematic analysis from the global burden of disease study 2019","volume":"2","author":"Global Burden Disease Fracture Collaborators","year":"2021","journal-title":"Lancet Healthy Longev"},{"issue":"8","key":"2026021918525313400_dgaf523-B3","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/jbmr.4821","article-title":"Global epidemiology of hip fractures: secular trends in incidence rate, post-fracture treatment, and all-cause mortality","volume":"38","author":"Sing","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026021918525313400_dgaf523-B4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11657-020-0706-y","article-title":"Fragility fractures in Europe: burden, management and opportunities","volume":"15","author":"Borgstr\u00f6m","year":"2020","journal-title":"Arch Osteoporos"},{"issue":"10329","key":"2026021918525313400_dgaf523-B5","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","article-title":"Drug therapy for osteoporosis in older adults","volume":"399","author":"Reid","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"2026021918525313400_dgaf523-B6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40266-025-01205-5","article-title":"Treatment considerations for severe osteoporosis in older adults","volume":"42","author":"See","year":"2025","journal-title":"Drugs Aging"},{"issue":"10117","key":"2026021918525313400_dgaf523-B7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"2026021918525313400_dgaf523-B8","doi-asserted-by":"crossref","first-page":"115516","DOI":"10.1016\/j.bone.2020.115516","article-title":"Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches","volume":"139","author":"Langdahl","year":"2020","journal-title":"Bone"},{"issue":"9886","key":"2026021918525313400_dgaf523-B9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"2026021918525313400_dgaf523-B10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11914-996-0011-8","article-title":"Combination\/sequential therapy in osteoporosis","volume":"2","author":"Lecart","year":"2004","journal-title":"Curr Osteoporos Rep"},{"issue":"3","key":"2026021918525313400_dgaf523-B11","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH (1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"13","key":"2026021918525313400_dgaf523-B12","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"issue":"19","key":"2026021918525313400_dgaf523-B13","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2015.15629","article-title":"Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force","volume":"316","author":"Chou","year":"2016","journal-title":"JAMA"},{"issue":"6257","key":"2026021918525313400_dgaf523-B14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","article-title":"Regulation of the mevalonate pathway","volume":"343","author":"Goldstein","year":"1990","journal-title":"Nature"},{"issue":"17","key":"2026021918525313400_dgaf523-B15","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1001\/archinte.165.17.2007","article-title":"Statin use and fracture risk: study of a US veterans' population","volume":"165","author":"Scranton","year":"2005","journal-title":"Arch Intern Med"},{"issue":"9222","key":"2026021918525313400_dgaf523-B16","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/S0140-6736(00)02400-4","article-title":"Inhibitors of hydroxymethylglutaryl- coenzyme A reductase and risk of fracture among older women","volume":"355","author":"Chan","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"2026021918525313400_dgaf523-B17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1359\/jbmr.2003.18.1.88","article-title":"The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity","volume":"18","author":"Staal","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2026021918525313400_dgaf523-B18","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1210\/en.2011-0016","article-title":"Effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation","volume":"152","author":"Weivoda","year":"2011","journal-title":"Endocrinology"},{"issue":"2","key":"2026021918525313400_dgaf523-B19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1006\/bbrc.2001.5597","article-title":"Pitavastatin enhanced BMP- 2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts","volume":"287","author":"Ohnaka","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"2026021918525313400_dgaf523-B20","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/jcb.20598","article-title":"Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts","volume":"96","author":"Viereck","year":"2005","journal-title":"J Cell Biochem"},{"issue":"5","key":"2026021918525313400_dgaf523-B21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10059-011-0107-6","article-title":"Simvastatin promotes osteogenic differentiation of mouse embryonic stem cells via canonical Wnt\/beta-catenin signaling","volume":"32","author":"Qiao","year":"2011","journal-title":"Mol Cells"},{"issue":"1","key":"2026021918525313400_dgaf523-B22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00198-016-3844-8","article-title":"Efficacy of statins for osteoporosis: a systematic review and meta-analysis","volume":"28","author":"An","year":"2017","journal-title":"Osteoporos Int"},{"issue":"22","key":"2026021918525313400_dgaf523-B23","doi-asserted-by":"crossref","first-page":"e3042","DOI":"10.1097\/MD.0000000000003042","article-title":"Effects of statins on bone mineral density and fracture risk: a PRISMA-compliant systematic review and meta-analysis","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2026021918525313400_dgaf523-B24","first-page":"191","article-title":"Fracture risk assessment in postmenopausal women referred to an Italian center for osteoporosis: a single day experience in Messina","volume":"10","author":"Catalano","year":"2013","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"20","key":"2026021918525313400_dgaf523-B25","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.3390\/jcm13206239","article-title":"Renal function is associated with changes in bone mineral density in postmenopausal osteoporotic women treated with denosumab: data from a retrospective cohort study","volume":"13","author":"Catalano","year":"2024","journal-title":"J Clin Med"},{"key":"2026021918525313400_dgaf523-B26","doi-asserted-by":"crossref","unstructured":"Oliveri C, Xourafa A, Morabito N, et al \u00a0Data from: Statins do not affect bone anabolism in older women treated with teriparatide. Zenodo \u00a02025. Deposited 3 September 2025. doi:10.5281\/zenodo.17049833.","DOI":"10.1210\/clinem\/dgaf523"},{"issue":"1","key":"2026021918525313400_dgaf523-B27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11914-025-00909-2","article-title":"Sequential and long-term therapy for osteoporosis","volume":"23","author":"McClung","year":"2025","journal-title":"Curr Osteoporos Rep"},{"issue":"5","key":"2026021918525313400_dgaf523-B28","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026021918525313400_dgaf523-B29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1186\/s12891-024-07860-w","article-title":"The effects of simvastatin on the bone microstructure and mechanics of ovariectomized mice: a micro-CT and micro-finite element analysis study","volume":"25","author":"Liang","year":"202418","journal-title":"BMC Musculoskelet Disord"},{"issue":"3","key":"2026021918525313400_dgaf523-B30","doi-asserted-by":"crossref","first-page":"e3603","DOI":"10.1002\/dmrr.3603","article-title":"Statin use in patients with type 2 diabetes has lower risk of hip fractures: a Taiwan national population-based study","volume":"39","author":"Lee","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"2026021918525313400_dgaf523-B31","doi-asserted-by":"crossref","first-page":"30825","DOI":"10.1038\/s41598-024-81628-z","article-title":"Association of higher potency statin use with risk of osteoporosis and fractures in patients with stroke in a Korean nationwide cohort study","volume":"14","author":"Jeong","year":"2024","journal-title":"Sci Rep"},{"key":"2026021918525313400_dgaf523-B32","doi-asserted-by":"crossref","first-page":"117425","DOI":"10.1016\/j.atherosclerosis.2023.117425","article-title":"Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: a sub-analysis of a randomized clinical trial","volume":"388","author":"Raggi","year":"2024","journal-title":"Atherosclerosis"},{"issue":"10","key":"2026021918525313400_dgaf523-B33","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00228-023-03544-x","article-title":"Influence of non-osteoporotic treatments in patients on active anti-osteoporotic therapy: evidence from the OSTEOMED registry","volume":"79","author":"Coco-Mart\u00edn","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"2026021918525313400_dgaf523-B34","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1161\/01.ATV.0000036417.43987.D8","article-title":"Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition","volume":"22","author":"Werner","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"2026021918525313400_dgaf523-B35","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1210\/jc.2014-1102","article-title":"Influence of vitamin D status on the effect of statins on bone mineral density and bone turnover markers in postmenopausal women","volume":"99","author":"Hern\u00e1ndez","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026021918525313400_dgaf523-B36","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3390\/nu13061878","article-title":"Vitamin D boosts alendronate tail effect on bone mineral density in postmenopausal women with osteoporosis","volume":"13","author":"Catalano","year":"2021","journal-title":"Nutrients"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf523\/64334137\/dgaf523.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/3\/e691\/64334137\/dgaf523.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/3\/e691\/64334137\/dgaf523.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:53:02Z","timestamp":1771545182000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/3\/e691\/8259913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,22]]},"published-print":{"date-parts":[[2026,2,20]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf523","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,9,22]]}}}